Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
Performance
1 day | +4.67% | ||
1 month | +11.08% | ||
3 months | +34.96% | ||
6 months | +47.88% | ||
Current year | +35.54% | ||
1 year | +73.16% | ||
3 years | -53.94% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Biopharmaceuticals
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
+4.67% | -.--% | +35.54% | +73.16% | 1.31B | ||
-0.17% | +3.18% | +0.82% | -5.34% | 91.94B | ||
-1.32% | +2.74% | -1.32% | -6.37% | 38.74B | ||
-2.83% | +0.22% | -12.88% | -27.02% | 32.82B | ||
-0.27% | +1.53% | +64.32% | +52.57% | 26.66B | ||
-0.20% | +7.49% | -16.31% | -11.69% | 15.32B | ||
+0.44% | -2.26% | -11.38% | +0.20% | 11.65B | ||
+13.03% | +44.70% | +173.10% | +471.13% | 10.37B | ||
-1.29% | -6.55% | -49.84% | -31.01% | 10.12B | ||
-1.07% | -2.05% | +3.82% | +27.16% | 9.06B | ||
+0.14% | +1.70% | -16.26% | -4.91% | 7.46B | ||
-0.20% | +1.74% | -4.48% | +3.93% | 7.22B | ||
-0.38% | +10.06% | +0.81% | +20.42% | 7.09B | ||
+1.50% | +4.65% | -7.12% | +4.94% | 6.77B | ||
-2.12% | -5.39% | -41.16% | -19.49% | 6.14B | ||
-0.26% | -3.43% | -32.99% | +69.06% | 5.06B | ||
Average | +0.60% | +4.46% | +5.29% | +38.55% | ||
Weighted average by Cap. | -0.19% | +3.64% | +5.87% | +17.08% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2024 | +35.54% | ||
2023 | +8.59% | ||
2022 | -41.95% | ||
2021 | -53.04% | ||
2020 | +15.21% | ||
2019 | -17.59% |
- Stock Market
- Equities
- 2696 Stock
- Quotes Shanghai Henlius Biotech, Inc.